Novo Nordisk ends 2022 triumphantly – and next year is looking even better
Though there have been ups and down, 2022 was one for the books for the pharmaceutical giant. Three upgrades and a positive stock development throughout the year have analysts swooning over next year’s potential.
by marketwire, translated by daniel pedersen
While stock markets have been marred by inflation and the war in Ukraine, Novo Nordisk has powered ahead with nice growth rates – and it might very well continue next year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA warns of shortage of Eli Lilly's diabetes drugs
For subscribers
Eli Lilly expects 2023 revenue to pass USD 30bn mark
For subscribers
